Company profile for Neuron23

NEW Drugs in Dev: 4
PharmaCompass

Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

Update your Virtual Booth on PharmaCompass, ask us

About

Neuron23 has assembled a world-class team of experts and entrepreneurs located in South San Francisco, USA, and Munich, Germany. Working with leading geneticists and valued partners like Origenis, Neuron23 leverages genetic breakthroughs and artificial intelligence technology to discover promising approaches and develop new drugs more efficiently than ever before.Neuron23 has a pipeline of preclinical, small molecule candidate...
Neuron23 has assembled a world-class team of experts and entrepreneurs located in South San Francisco, USA, and Munich, Germany. Working with leading geneticists and valued partners like Origenis, Neuron23 leverages genetic breakthroughs and artificial intelligence technology to discover promising approaches and develop new drugs more efficiently than ever before.Neuron23 has a pipeline of preclinical, small molecule candidates, licensed as part of a drug discovery partnership with Origenis. Our lead candidate targets LRRK2 as a potential treatment for Parkinson’s Disease. Founded in 2018

List your booth number for exhibitions, ask us

CONTACT DETAILS

Click the arrow to open the dropdown
Country
Country
U.S.A
Address
Address
681 Gateway Blvd. 3rd Floor South San Francisco, CA 94080
Telephone
Telephone
youtube
YouTube
Twitter
Twitter

Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

Events

Webinars & Exhibitions

Tides Asia

Tides Asia

Not Confirmed

envelop Contact Supplier

Tides Asia

Post an Enquiry

Meeting

Digital content

Create Content with PharmaCompass, ask us

NEWS #PharmaBuzz

read-more
read-more

https://www.businesswire.com/news/home/20250624403818/en/Neuron23-Announces-%2496.5-Million-Series-D-Financing-and-First-Patient-Dosed-in-Global-Phase-2-NEULARK-Clinical-Trial-of-NEU-411-for-Early-Parkinsons-Disease

BUSINESSWIRE
24 Jun 2025

https://www.businesswire.com/news/home/20250325730888/en/Neuron23-Announces-Publication-in-PNAS-Highlighting-the-Important-Role-of-TYK2-in-Neuroimmunology

BUSINESSWIRE
25 Mar 2025

https://www.businesswire.com/news/home/20250324486856/en/Neuron23-to-Present-Phase-1-Healthy-Volunteer-Data-of-NEU-411-a-Brain-penetrant-LRRK2-Inhibitor-at-ADPD-2025

BUSINESSWIRE
24 Mar 2025

https://www.businesswire.com/news/home/20241203225285/en

BUSINESSWIRE
03 Dec 2024

https://www.businesswire.com/news/home/20241119938450/en

BUSINESSWIRE
19 Nov 2024

https://www.businesswire.com/news/home/20241119574234/en

BUSINESSWIRE
19 Nov 2024

ABOUT THIS PAGE

Ask Us for Pharmaceutical Supplier and Partner
Ask Us, Find A Supplier / Partner
No Commissions, No Strings Attached, Get Connected for FREE

What are you looking for?

How can we help you?

The request can't be empty

Please read our Privacy Policy carefully

You must agree to the privacy policy

The name can't be empty
The company can't be empty.
The email can't be empty Please enter a valid email.
The mobile can't be empty